September 17, 2024
BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer, according to results of […]
September 17, 2024
TOPLINE: Adenosine is safe for treating supraventricular tachycardia (SVT) in children in emergency settings, and patients have not experienced sustained ventricular tachycardia or prolonged cardiac pauses […]
September 17, 2024
CHICAGO — Less than 4% of American women aged 50-59 years use hormone therapy (HT) to treat menopausal symptoms today, approximately 10 times lower than the […]
September 17, 2024
(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal in a late-stage study in some patients with a […]
September 17, 2024
WASHINGTON (Reuters) – The U.S. Senate is set to vote on Tuesday on a bill to enshrine federal protections and expand insurance coverage for fertility treatments, […]
September 17, 2024
WASHINGTON (Reuters) -A U.S. Senate bill aimed at enshrining federal protections and expanding insurance coverage for fertility treatments failed on Tuesday, as Republicans voted against it […]
September 17, 2024
For decades, public health officials, researchers, and clinicians have worked hand in hand with government officials to stem the rise of preventable and treatable sexually transmitted […]
September 17, 2024
CHICAGO — The vast majority of women experiencing genitourinary syndrome of menopause (GSM) symptoms did not receive a prescription for hormonal vaginal therapies prior to seeking […]
September 17, 2024
TOPLINE: Children with hidradenitis suppurativa (HS) are more likely to have obesity than those without the condition, a review suggests. METHODOLOGY: To evaluate the relationship between […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487
Next page